Efficient Gene Editing for Heart Disease via ELIP-Based CRISPR Delivery System

    February 2024 in “ Pharmaceutics ”
    Xing Yin, Romain Harmancey, Brion Frierson, Jean Wu, Melanie R. Moody, David D. McPherson, Shaoling Huang
    Studysummary This study found that echogenic liposomes improved the delivery and penetration of CRISPR/Cas9 genetic materials into cardiomyocytes, both in vitro and in vivo, especially when combined with ultrasound, highlighting a promising strategy for cardiovascular gene therapy.
    Our plain-language summary. Not medical advice or a treatment recommendation. Consult a qualified healthcare professional before changing treatment. Full disclaimer
    The study investigates the use of echogenic liposomes (ELIP) combined with ultrasound as a delivery system for CRISPR/Cas9 complexes targeting heart disease. It demonstrates that ELIP significantly enhances the delivery and gene editing efficiency in cardiomyocytes both in vitro and in vivo, using mouse neonatal ventricular myocytes and rat hearts. The method showed improved penetration and effectiveness of gene editing, achieving up to 59.6% cleavage efficiency, and offers a promising non-invasive approach for targeted gene therapy in heart diseases. However, further optimization and extensive preclinical testing are needed to ensure safety and efficacy.
    Discuss this study in the Community →

    Research cited in this study

    2 / 2 results